Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 428 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR From smart knives to virtual reality tumours: five innovations in understanding... August 29, 2022 Daughter Donates Hair to Mother After She Was Diagnosed with Stage... March 3, 2021 Study Says Educational Materials for Chemo Often Require Higher Reading Level... September 25, 2019 5-Yr-Old Cancer Survivor Used His Birthday To Collect Toys For Sick... October 15, 2019 Load more HOT NEWS Higher Rates of Metastasis-Free Survival in Men with High-Risk Non-Metastatic Prostate... European Lung Cancer Virtual Congress 2021, 25-27 March [Event Announcement] New plan unveiled to tackle Scotland’s cancer crisis Shaping Cancer Care in Asia: ESMO Brings Research and Patient Voices...
